Addus HomeCare Co. (NASDAQ:ADUS – Get Free Report) CEO R Dirk Allison sold 12,500 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $123.16, for a total transaction of $1,539,500.00. Following the transaction, the chief executive officer now owns 141,897 shares of the company’s stock, valued at $17,476,034.52. This represents a 8.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Addus HomeCare Stock Performance
Addus HomeCare stock opened at $121.29 on Thursday. The company has a market capitalization of $2.20 billion, a PE ratio of 27.76, a price-to-earnings-growth ratio of 2.15 and a beta of 1.04. Addus HomeCare Co. has a fifty-two week low of $85.43 and a fifty-two week high of $136.12. The firm has a 50 day moving average price of $127.91 and a 200 day moving average price of $123.51.
Addus HomeCare (NASDAQ:ADUS – Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.02. Addus HomeCare had a return on equity of 9.62% and a net margin of 6.50%. The business had revenue of $289.80 million during the quarter, compared to analysts’ expectations of $289.42 million. During the same period in the previous year, the firm posted $1.03 earnings per share. The company’s revenue was up 7.1% on a year-over-year basis. As a group, equities research analysts forecast that Addus HomeCare Co. will post 4.58 earnings per share for the current year.
Institutional Trading of Addus HomeCare
Analyst Ratings Changes
A number of analysts have recently commented on the stock. KeyCorp started coverage on shares of Addus HomeCare in a research note on Friday, October 11th. They set an “overweight” rating and a $150.00 target price for the company. Oppenheimer increased their target price on shares of Addus HomeCare from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Macquarie reissued an “outperform” rating and set a $139.00 price objective on shares of Addus HomeCare in a research note on Monday, November 4th. TD Cowen boosted their target price on shares of Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $136.00 price target on shares of Addus HomeCare in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $131.63.
Read Our Latest Stock Report on Addus HomeCare
About Addus HomeCare
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.
Read More
- Five stocks we like better than Addus HomeCare
- What is a Death Cross in Stocks?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Transportation Stocks Investing
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Addus HomeCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus HomeCare and related companies with MarketBeat.com's FREE daily email newsletter.